GlassScriptPhysician profile
Carl A Blau
NPI 1881779619
$15,448.14
in general payments reported to CMS, 2019-2025
11 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.99 · 2021: $4,550 · 2022: $1,604 · 2023: $8,967 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,030 · Travel and Lodging: $1,734 · Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,030.00 |
| Travel and Lodging | $1,734.49 |
| Food and Beverage | $516.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,928.48 | 2023 | |
| Glaxosmithkline, LLC. | $4,550.00 | 2021 | |
| Janssen Biotech, INC. | $1,280.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $227.18 | 2022-2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $134.98 | 2022 | |
| Caris Mpi, INC. | $126.21 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $124.97 | 2022 | |
| Genzyme Corporation | $38.51 | 2023 | |
| Pfizer INC. | $24.82 | 2025 | |
| Genentech, INC. | $12.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Blau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.